BrainX Corporation   Report issue

For profit Phase 2
Founded: Camarillo CA United States (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2018
NCT03413384
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

BrainX Corporation

Active Ingredients

Drugs in Phase 2 Trials (1)

ceftriaxone (rocephin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dementia (Phase 2)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1